NBIX News and Press, Neurocrine Biosciences Inc. From 11/13/23

Neurocrine Biosciences Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation PR Newswire SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), a leading neuroscience-focused biopharmaceutical company,...

2023-11-09 16:56:54 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Call Transcript Neurocrine Biosciences, Inc. 2023 Q3 - Results - Earnings Call Presentation Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To...

Neurocrine Biosciences Provides Development Pipeline Update PR Newswire Phase 2 Proof-of-Concept Study of NBI-921352 in Patients with Focal Onset Seizures Failed to Demonstrate Meaningful Reduction in Seizure Frequency Phase 2 Proof-of-Concept Study of NBI-106584...

Neurocrine Biosciences Launches Interactive Digital Tool for use by Healthcare Providers to Help Expand Education on Identifying and Diagnosing Tardive Dyskinesia PR Newswire SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)...

Neurocrine Biosciences to Present at the Jefferies London Healthcare Conference PR Newswire SAN DIEGO , Nov. 8, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Jefferies London Healthcare Conference on Tuesday November 14, 2...

Neurocrine Biosciences® Presents INGREZZA® (valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated With Huntington's Disease Through Week 50 at Huntington Study Group 2023 PR Newswire SAN DIEGO , Nov. 2, 2023 /PRNew...

2023-10-31 14:30:25 ET Neurocrine Biosciences, Inc. (NBIX) Q3 2023 Earnings Conference Call October 31, 2023, 8:00 AM ET Company Participants Todd Tushla - Vice President, Investor Relations Kevin Gorman - Chief Executive Officer Matt Abernethy - Chief Financial ...

2023-10-31 07:07:10 ET More on Neurocrine Biosciences Neurocrine's Crinecerfont Delivered, But The Street Has Been Slow To Reward The Success Neurocrine Needs A Meaningful Clinical Win To Break Out, And Crinecerfont Could Do It Neurocrine Biosciences: Ingrezza Impres...

Tennant Company (TNC) is expected to report for Q3 2023 Stellantis N.V. (STLA) is expected to report for Q3 2023 Marathon Petroleum Corporation (MPC) is expected to report $7.79 for Q3 2023 Easterly Government Properties Inc. (DEA) is expected to report $0.29 for Q3 2023 Allegion ...

Neurocrine Biosciences Reports Third Quarter 2023 Financial Results and Raises 2023 INGREZZA Sales Guidance PR Newswire INGREZZA ® (valbenazine) Third Quarter Net Product Sales of $486 Million Representing 29% Year-Over-Year Growth INGREZZA ® ...